Press Releases | Mylan http://newsroom.mylan.com/ MediaRoom Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering http://newsroom.mylan.com/2018-12-17-Launch-of-Generic-Lialda-R-Delayed-Release-Tablets-Expands-Mylans-Gastroenterology-Product-Offering Mesalamine Delayed-Release Tablets help individuals manage their ulcerative colitis. Mon, 17 Dec 2018 10:45:00 -0500 http://newsroom.mylan.com/2018-12-17-Launch-of-Generic-Lialda-R-Delayed-Release-Tablets-Expands-Mylans-Gastroenterology-Product-Offering Mylan Adds First Generic for Canasa® Rectal Suppository to Growing Gastroenterology Portfolio http://newsroom.mylan.com/2018-12-17-Mylan-Adds-First-Generic-for-Canasa-R-Rectal-Suppository-to-Growing-Gastroenterology-Portfolio Mylan's Mesalamine Rectal Suppository treats mildly to moderately active ulcerative proctitis Mon, 17 Dec 2018 10:30:00 -0500 http://newsroom.mylan.com/2018-12-17-Mylan-Adds-First-Generic-for-Canasa-R-Rectal-Suppository-to-Growing-Gastroenterology-Portfolio Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan http://newsroom.mylan.com/2018-12-13-Sanofis-Formulation-Patents-on-Multibillion-Dollar-Lantus-R-are-Invalidated-by-U-S-Patent-and-Trademark-Office-via-IPR-Announces-Mylan Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials Thu, 13 Dec 2018 07:30:00 -0500 http://newsroom.mylan.com/2018-12-13-Sanofis-Formulation-Patents-on-Multibillion-Dollar-Lantus-R-are-Invalidated-by-U-S-Patent-and-Trademark-Office-via-IPR-Announces-Mylan Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient http://newsroom.mylan.com/2018-12-04-Mylan-Expands-its-Voluntary-Nationwide-Recall-of-Valsartan-Tablets-USP-Amlodipine-and-Valsartan-Tablets-USP-and-Valsartan-and-Hydrochlorothiazide-Tablets-USP-to-All-Lots-Within-Expiry-Due-to-the-Detection-of-Trace-Amounts-of-NDEA-N-Nitrosodieth Tue, 04 Dec 2018 11:30:00 -0500 http://newsroom.mylan.com/2018-12-04-Mylan-Expands-its-Voluntary-Nationwide-Recall-of-Valsartan-Tablets-USP-Amlodipine-and-Valsartan-Tablets-USP-and-Valsartan-and-Hydrochlorothiazide-Tablets-USP-to-All-Lots-Within-Expiry-Due-to-the-Detection-of-Trace-Amounts-of-NDEA-N-Nitrosodieth Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets http://newsroom.mylan.com/2018-12-04-Mylan-Expands-Gastroenterology-Portfolio-with-Launch-of-Generic-for-Prevacid-R-SoluTab-Delayed-Release-Orally-Disintegrating-Tablets Mylan's Lansoprazole Delayed-Release Orally Disintegrating Tablets are approved to treat certain types of gastrointestinal ulcers Tue, 04 Dec 2018 07:30:00 -0500 http://newsroom.mylan.com/2018-12-04-Mylan-Expands-Gastroenterology-Portfolio-with-Launch-of-Generic-for-Prevacid-R-SoluTab-Delayed-Release-Orally-Disintegrating-Tablets